Genus plc (LON:GNS – Get Free Report) insider Celia Baxter acquired 1,728 shares of Genus stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of GBX 2,893 per share, with a total value of £49,991.04.
Genus Trading Up 2.6%
Shares of GNS opened at GBX 2,915 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12. The firm’s 50-day moving average is GBX 2,845.83 and its two-hundred day moving average is GBX 2,648.45. Genus plc has a twelve month low of GBX 1,548 and a twelve month high of GBX 3,220. The firm has a market capitalization of £1.94 billion, a P/E ratio of 100.87, a PEG ratio of 2.87 and a beta of 0.37.
Genus (LON:GNS – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported GBX 60.80 earnings per share (EPS) for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. On average, research analysts predict that Genus plc will post 70.9644323 earnings per share for the current fiscal year.
Analyst Ratings Changes
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Featured Stories
- Five stocks we like better than Genus
- 1,500 Banks Just Handed the Fed Your Bank Account
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Buy this stock tomorrow?
- Elon Musk already made me a “wealthy man”
- Sell this, buy that
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
